Compare SKWD & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKWD | NUVB |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2022 | 2020 |
| Metric | SKWD | NUVB |
|---|---|---|
| Price | $58.76 | $4.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $70.45 | $13.00 |
| AVG Volume (30 Days) | 310.2K | ★ 5.1M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.81 | ★ 71.56 |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $1,416,541,000.00 | $62,902,000.00 |
| Revenue This Year | $39.34 | $211.79 |
| Revenue Next Year | $6.68 | $45.15 |
| P/E Ratio | $27.33 | ★ N/A |
| Revenue Growth | 23.16 | ★ 698.96 |
| 52 Week Low | $40.60 | $3.36 |
| 52 Week High | $65.69 | $9.75 |
| Indicator | SKWD | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 29.49 |
| Support Level | $55.18 | $4.10 |
| Resistance Level | $58.81 | $5.16 |
| Average True Range (ATR) | 1.47 | 0.24 |
| MACD | 0.59 | -0.06 |
| Stochastic Oscillator | 83.12 | 20.80 |
Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.